
LENZ Stock Forecast & Price Target
LENZ Analyst Ratings
Bulls say
LENZ Therapeutics is experiencing a flat quarter over quarter revenue for VIZZ, but new initiatives such as telehealth and a national TV campaign have the potential to significantly increase e-pharmacy prescriptions and drive acceleration in the VIZZ launch. Though there is currently minimal ciliary muscle stimulation in its mechanism, the company must see significant growth in the next few quarters to maintain a sustainable business model and is watching spending closely. The company's new telehealth prescribing option may introduce risk for patients with underlying retinal concerns, and its success will depend on the comprehensiveness and effectiveness of the screening questionnaire. With a reduced price target of $38 per share, this analyst maintains a Buy rating on the stock, factoring in a 25% estimated peak penetration rate and adjusted expense estimates.
Bears say
LENZ Therapeutics is facing potential competition and safety concerns with its presbyopia eye drop VIZZ, impacting its future commercial success. Despite recently announced initiatives such as the expansion of the sales force and a DTC campaign, there are still risks and uncertainties in securing market share and sustaining growth in the highly competitive ophthalmology market. Additionally, the company's valuation and financials may be negatively impacted if it fails to meet peak revenue estimates and secure sufficient funding for operations.
This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LENZ Analyst Forecast & Price Prediction
Start investing in LENZ
Order type
Buy in
Order amount
Est. shares
0 shares